Description
N/A
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
N/A
1 week
0%
1 month
9.62%
YTD
-19.72%
1 year
-32.14%
All time high
N/A
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
N/A
Short Sell (% of issue)
N/A
Date | Announcements |
---|---|
31 October 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 October 22 |
Neurotech Receives $1.2M R&D Tax Rebate
×
Neurotech Receives $1.2M R&D Tax Rebate |
31 October 22 |
Annual Report (Typeset)
×
Annual Report (Typeset) |
31 October 22 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
31 May 23 |
NTI Granted 2 Year Extension of Treatment for ASD Patients
×
NTI Granted 2 Year Extension of Treatment for ASD Patients |
31 January 23 |
Application for quotation of securities - NTI
×
Application for quotation of securities - NTI |
31 January 23 |
Distribution Schedule
×
Distribution Schedule |
31 January 23 |
Top 20 securityholders
×
Top 20 securityholders |
31 January 23 |
Application for quotation of securities - NTI
×
Application for quotation of securities - NTI |
31 January 23 |
Secondary Trading Notice
×
Secondary Trading Notice |
31 January 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 August 23 |
Last Patient Completes Treatment in NTIPANS1 Clinical Trial
×
Last Patient Completes Treatment in NTIPANS1 Clinical Trial |
31 August 22 |
Appendix 4E & Annual Report
×
Appendix 4E & Annual Report |
31 August 22 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
31 August 20 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
31 August 20 |
Appendix 4E and Annual Report Updated
×
Appendix 4E and Annual Report Updated |
30 November 23 |
Application for quotation of securities - NTI
×
Application for quotation of securities - NTI |
30 November 22 |
Chairman Address to 2022 Annual General Meeting
×
Chairman Address to 2022 Annual General Meeting |
30 November 22 |
2022 Annual General Meeting Presentation
×
2022 Annual General Meeting Presentation |
30 November 22 |
Results of Meeting
×
Results of Meeting |
30 November 18 |
Chairman's Address, 2018 Annual General Meeting
×
Chairman's Address, 2018 Annual General Meeting |
30 November 18 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
30 November 18 |
Clarification - Results of Annual General Meeting
×
Clarification - Results of Annual General Meeting |
30 May 23 |
NTI granted HREC Approval for PANDAS/PANS Trial Extension
×
NTI granted HREC Approval for PANDAS/PANS Trial Extension |
30 June 23 |
Notification of cessation of securities - NTI
×
Notification of cessation of securities - NTI |
30 January 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 August 23 |
Appendix 4E & Annual Report
×
Appendix 4E & Annual Report |
30 August 23 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.